MTOR and breast cancer: The selective cytotoxicity of Oridonin in p-AKTHigh breast cancer cells provides a therapeutic advantage that cannot be achieved by the pan PI3K inhibitor BKM120, dual PI3K/mTOR inhibitor BEZ235, AKT inhibitor MK2206 (Supplementary Figure 4).